Literature DB >> 26225164

Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.

Scott A North1, Naveen Basappa2, Joan Basiuk3, Georg Bjarnason4, Rodney Breau5, Christina Canil6, Daniel Heng7, Michael A S Jewett8, Anil Kapoor9, Christian Kollmannsberger10, Kylea Potvin11, M Neil Reaume12, J Dean Ruether7, Peter Venner1, Lori Wood13.   

Abstract

Entities:  

Year:  2015        PMID： 26225164      PMCID： PMC4479636          DOI： 10.5489/cuaj.2894

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  47 in total

1.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Renal cell carcinoma bone metastases: clinical advances.

Authors:  Chakshu Sahi; Jennifer J Knox; Mark Clemons; Anthony M Joshua; Reuben Broom
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

4.  Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.

Authors:  Georg A Bjarnason; Bishoy Khalil; John M Hudson; Ross Williams; Laurent M Milot; Mostafa Atri; Alex Kiss; Peter N Burns
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

5.  Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.

Authors:  Michael R Abern; Emelian Scosyrev; Matvey Tsivian; Edward M Messing; Thomas J Polascik; Arkadiusz Z Dudek
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

6.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Authors:  Daniel Y C Heng; J Connor Wells; Brian I Rini; Benoit Beuselinck; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Sumanta Kumar Pal; Christian K Kollmannsberger; Takeshi Yuasa; Sandy Srinivas; Frede Donskov; Aristotelis Bamias; Lori A Wood; D Scott Ernst; Neeraj Agarwal; Ulka N Vaishampayan; Sun Young Rha; Jenny J Kim; Toni K Choueiri
Journal:  Eur Urol       Date:  2014-06-13       Impact factor: 20.096

7.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

8.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

9.  Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement.

Authors: 
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

10.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544
View more
  12 in total

1.  [Not Available].

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

2.  Codifying active surveillance.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

3.  Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.

Authors:  Sara Nazha; Simon Tanguay; Anil Kapoor; Michael Jewett; Christian Kollmannsberger; Lori Wood; G A Georg Bjarnason; Daniel Heng; Denis Soulières; Martin Neil Reaume; Naveen Basappa; Eric Lévesque; Alice Dragomir
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

Review 4.  Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Authors:  Naveen S Basappa
Journal:  Can Urol Assoc J       Date:  2016 Nov-Dec       Impact factor: 1.862

Review 5.  First-line treatment options in metastatic renal cell cancer.

Authors:  Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2016 Nov-Dec       Impact factor: 1.862

6.  Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Authors:  Sebastien J Hotte; Anil Kapoor; Naveen S Basappa; Georg Bjarnason; Christina Canil; Henry J Conter; Piotr Czaykowski; Jeffrey Graham; Samantha Gray; Daniel Y C Heng; Pierre I Karakiewicz; Christian Kollmannsberger; Aly-Khan A Lalani; Scott A North; François Patenaude; Denis Soulières; Phillippe Violette; Eric Winquist; Lori A Wood; Shaan Dudani; Ranjena Maloni; M Neil Reaume
Journal:  Can Urol Assoc J       Date:  2019-10       Impact factor: 1.862

7.  The impact of targeted therapy on healthcare resource use in patients with metastatic renal cell carcinoma: The University of Sherbrooke experience.

Authors:  Hugo Simard; Robert Sabbagh; Simon Ouellet; Patrick Richard; Claudio Jeldres
Journal:  Can Urol Assoc J       Date:  2018-05-14       Impact factor: 1.862

8.  Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.

Authors:  S Nazha; S Tanguay; A Kapoor; M Jewett; C Kollmannsberger; L Wood; G Bjarnason; D Heng; D Soulières; N Reaume; N Basappa; E Lévesque; A Dragomir
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

9.  Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Authors:  M Neil Reaume; Naveen S Basappa; Lori Wood; Anil Kapoor; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Patrick Cheung; Henry J Conter; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Pierre I Karakiewicz; Christian Kollmannsberger; Francois Patenaude; Alan So; Denis Soulières; Peter Venner; Phillippe Violette; Pawel Zalewski; Heather Chappell; Scott A North
Journal:  Can Urol Assoc J       Date:  2017-10       Impact factor: 1.862

Review 10.  Contemporary Treatment of Metastatic Renal Cell Carcinoma.

Authors:  Igor Stukalin; Nimira Alimohamed; Daniel Y C Heng
Journal:  Oncol Rev       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.